Tandutinib inhibits FMS receptor signalling, and macrophage and osteoclast formation in vitro

Leukemia

Volumn 22, Issue 7, 2008, Pages 1452-1453

  Brownlow, N ^a   Vaid, M ^a   Dibb, N J ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

4 [6 METHOXY 7 [3 (1 PIPERIDINYL)PROPOXY] 4 QUINAZOLINYL] 1 PIPERAZINECARBOXYLIC ACID (4 ISOPROPOXYPHENYL)AMIDE; ASPARTIC ACID; COLONY STIMULATING FACTOR RECEPTOR; IMATINIB; VALINE;

ANIMAL CELL; CELL GROWTH; COLONY FORMATION; CONTROLLED STUDY; DRUG MECHANISM; GENE MUTATION; HEMATOPOIETIC CELL; IC 50; IN VITRO STUDY; LETTER; MACROPHAGE; MOUSE; NONHUMAN; OSTEOCLAST; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RAT; SIGNAL TRANSDUCTION; WILD TYPE;

ANIMALS; CELL LINE; HUMANS; INTERLEUKIN-3; MACROPHAGE COLONY-STIMULATING FACTOR; MACROPHAGES; MICE; OSTEOCLASTS; PHOSPHORYLATION; PIPERAZINES; PROTEIN KINASE INHIBITORS; QUINAZOLINES; RATS; RECEPTOR, MACROPHAGE COLONY-STIMULATING FACTOR; SIGNAL TRANSDUCTION;

EID: 47549099826     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/sj.leu.2405085     Document Type: Letter

References (8)

1. DeAngelo DJ, Stone RM, Heaney ML, Nimer SD, Paquette RL, Klisovic RB et al. Phase 1 clinical results with tandutinib (MLN518), a novel FLT3 antagonist, in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome: Safety, pharmacokinetics, and pharmacodynamics. Blood 2006; 108: 3674-3681.
2. Reilly JT. Class III receptor tyrosine kinases: Role in leukaemogenesis. Br J Haematol 2002; 116: 744-757.
3. Kelly LM, Yu JC, Boulton CL, Apatira M, Li J, Sullivan CM et al. CT53518, a novel selective FLT3 antagonist for the treatment of acute myelogenous leukemia (AML). Cancer Cell 2002; 1: 421-432.
4. Ohno H, Kubo K, Murooka H, Kobayashi Y, Nishitoba T, Shibuya M et al. A c-fms tyrosine kinase inhibitor, Ki20227, suppresses osteoclast differentiation and osteolytic bone destruction in a bone metastasis model. Mol Cancer Ther 2006; 5: 2634-2643.
5. Murray LJ, Abrams TJ, Long KR, Ngai TJ, Olson LM, Hong W et al. SU11248 inhibits tumor growth and CSF-1R-dependent osteolysis in an experimental breast cancer bone metastasis model. Clin Exp Metastasis 2003; 20: 757-766.
6. Condeelis J, Pollard JW. Macrophages: Obligate partners for tumor cell migration, invasion, and metastasis. Cell 2006; 124: 263-266.
7. Clark JJ, Cools J, Curley DP, Yu JC, Lokker NA, Giese NA et al. Variable sensitivity of FLT3 activation loop mutations to the small molecule tyrosine kinase inhibitor MLN518. Blood 2004; 104: 2867-2872.
8. Brownlow N, Russell AE, Saravanapavan H, Wiesmann M, Murray JM, Manley PW et al. Comparison of nilotinib and imatinib inhibition of FMS receptor signaling, macrophage production and osteoclastogenesis. Leukemia 2007; e-pub ahead of print 13 September 2007.